The current P/E ratio of ANIK can't be determined, as the TTM EPS of -$6.65 is negative. The most recent PE ratio recorded for Anika Therapeutics was 123.55 in December 2021.
Over the last ten years, the average PE ratio of Anika Therapeutics has been 28.13. In the past ten years, ANIK's PE ratio reached its highest point in the Dec 2021 quarter at 123.55, with a price of $35.83 and an EPS of $0.29. The Mar 2020 quarter saw the lowest point at 14.31, with a price of $28.91 and an EPS of $2.02.
Maximum annual increase: 150.95% in 2009
Maximum annual decrease: -40.28% in 2014
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2023 | N/A | N/A | $22.66 | -$5.64 |
2022 | N/A | N/A | $29.6 | -$1.02 |
2021 | 123.55 | N/A | $35.83 | $0.29 |
2020 | N/A | N/A | $45.26 | -$1.69 |
2019 | 26.87 | 3.95% | $51.85 | $1.93 |
2018 | 25.85 | 4.53% | $33.61 | $1.3 |
2017 | 24.73 | 12.15% | $53.91 | $2.18 |
2016 | 22.05 | 19.06% | $48.96 | $2.22 |
2015 | 18.52 | 18.64% | $38.16 | $2.06 |
2014 | 15.61 | -40.28% | $40.74 | $2.61 |
2013 | 26.14 | 134.02% | $38.16 | $1.46 |
2012 | 11.17 | -25.93% | $9.94 | $0.89 |
2011 | 15.08 | -23.14% | $9.8 | $0.65 |
2010 | 19.62 | -17.7% | $6.67 | $0.34 |
2009 | 23.84 | 150.95% | $7.63 | $0.32 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Sep 2024 | N/A | N/A | $24.7 | -$6.65 |
Jun 2024 | N/A | N/A | $25.33 | -$5.07 |
Mar 2024 | N/A | N/A | $25.4 | -$5.25 |
Dec 2023 | N/A | N/A | $22.66 | -$5.64 |
Sep 2023 | N/A | N/A | $18.63 | -$1.69 |
Jun 2023 | N/A | N/A | $25.98 | -$1.53 |
Mar 2023 | N/A | N/A | $28.72 | -$1.54 |
Dec 2022 | N/A | N/A | $29.6 | -$1.02 |
Sep 2022 | N/A | N/A | $23.8 | -$1.09 |
Jun 2022 | N/A | N/A | $22.32 | -$0.76 |
Mar 2022 | N/A | N/A | $25.11 | -$0.11 |
Dec 2021 | 123.55 | N/A | $35.83 | $0.29 |
Sep 2021 | N/A | N/A | $42.56 | -$0.41 |
Jun 2021 | N/A | N/A | $43.29 | -$0.9 |
Mar 2021 | N/A | N/A | $40.79 | -$1.89 |
Stock name | PE ratio | Market cap |
---|---|---|
HALO Halozyme Therapeutics Inc | 16.5 | $7.11B |
MDT Medtronic plc | 27.34 | $115.33B |
JNJ Johnson & Johnson | 27.79 | $390.76B |
STAA Staar Surgical Co | 38.34 | $831.28M |
SYK Stryker Corp | 48.7 | $146.06B |
ANIK Anika Therapeutics Inc | N/A | $254.69M |
The current price to earnings ratio of ANIK can't be calculated, as its EPS of -$6.65 is negative.
The highest quarterly PE ratio in the last ten years has been 123.55 and it was in the Dec 2021 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.